Abstract
The 5-year survival rate of patients with head and neck squamous cell carcinoma (HNSCC) was only 40%-50%. To investigate the prognostic and predictive value of specific mircoRNAs (miRNAs) in HNSCC. We identified 19 miRNAs associated with over survival (OS) of patients with HNSCC in different clinical classes between 492 HNSCC tissues and 44 normal tissues from The Cancer Genome Atlas (TCGA) dataset. A signature of six miRNAs was identified by the supervised principal component method in the training set. The AUC of the ROC curve for the six microRNA signature predicting 5-year survival was 0.737 (95%CI, 0.627-0.825) in the testing set and 0.708 (95%CI, 0.616-0.785) in the total dataset. In the multivariate Cox regression analysis, patients with high-risk scores had shorter OS (HR, 2.380, 95%CI, 1.361-4.303) than patients with low-risk scores in the total dataset. Therefore, these results provided a new prospect for prognostic biomarker of HNSCC.
Highlights
Head and neck squamous cell carcinoma (HNSCC) originates from the upper aerodigestive tract including oral cavity, oropharynx, hypopharynx and larynx, which is the sixth most common cancer
MiRNAs have been reported in all stages of neoplastic progression including apoptosis, proliferation, progression, metastasis, invasion, and relapse [17]
Hsa-miR-203 may be used as a predictive marker of survival in laryngeal squamous cell carcinoma patients because the expression of hsamiR-203 was associated with lymph node metastasis, advanced clinical stages, and decreased 5-year survival rate [22, 23]
Summary
Head and neck squamous cell carcinoma (HNSCC) originates from the upper aerodigestive tract including oral cavity, oropharynx, hypopharynx and larynx, which is the sixth most common cancer. Studies had previously found that some circulating miRNAs strongly associates with the invasion, and metastasis of cancer [9]. Circulating miRNAs may be a potential novel biomarkers for cancer detection and prognosis. A 4-miRNAs panel was associated with overall survival of patients with non-small cell lung cancer [10]. Hsa-miR-25 is associated with poor survival of gastric cancer patients by inhibiting transducer of ERBB2 [12]. Hsa-miR-7 expression is associated with poor prognosis via EGFR regulation in colorectal cancer [13]. Other studies showed that high expression www.impactjournals.com/oncotarget of hsa-miR-19a and hsa-miR-21 and low expression of hsa-miR-375 were associated with shorter overall survival in laryngeal squamous cell carcinoma patients [14,15,16]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
